Analysis Editas Medicine, Inc. (0IFK)
5/30/2024
Analysis of Editas Medicine, Inc. (0IFK)
Editas Medicine, Inc. is a biotechnology company that focuses on developing gene editing technologies. Looking at the provided data for stock symbol 0IFK, we can see that the price has been fluctuating over the past few days.The Relative Strength Index (RSI) values indicate that the stock has been in the overbought territory, with values above 70, suggesting a possible reversal or correction in the near future.
The Moving Average Convergence Divergence (MACD) indicator shows positive values, indicating a bullish trend. The MACD histogram is also positive, suggesting upward momentum.
The Moving Average (MA) indicator values are increasing, indicating a positive trend in the stock price.
Overall, based on the technical indicators, it seems that the stock of Editas Medicine, Inc. may be in a bullish phase. However, investors should also consider other fundamental factors before making any investment decisions.
Income statement 💸
These are the revenues. Here are the conclusions:1. The company's sales have been increasing steadily over the past four years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. The gross profit margin has fluctuated slightly, with the highest gross profit of $170.8 billion in 2022 and the lowest of $104.9 billion in 2020.
3. Operating income has also shown an increasing trend, reaching $114.3 billion in 2023 from $66.3 billion in 2020.
4. Net income has been on the rise, with the company making $99.8 billion in 2022 compared to $57.4 billion in 2020.
5. Earnings per share (EPS) have shown a slight fluctuation but have generally increased over the years, with diluted EPS reaching $6.13 in 2023 from $3.28 in 2020.
6. The company has been able to maintain a healthy EBITDA margin, with EBITDA reaching $129.2 billion in 2023.
7. Despite an increase in income tax expenses, the company has managed to grow its net income continuously over the years.
8. The company has been investing in research and development, as well as selling, general, and administrative expenses, to support its growth in sales and profitability.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets include cash, inventory, and receivables, with a significant portion in cash equivalents and short-term investments.
3. Non-current assets consist of leases, land, machinery, and investments.
4. Total liabilities have also been increasing, but at a slower pace compared to assets.
5. Shareholders' equity has shown fluctuations but has generally been positive.
6. The company has been investing in both current and non-current assets to support its operations and growth.
7. There is a mix of short-term and long-term liabilities, with a provision for risks and charges included.
8. Retained earnings have varied over the years, impacting the overall shareholders' equity.
9. The company seems to be managing its debt levels while focusing on asset growth and maintaining a positive equity position.
Earnings
The company's results for the most recent quarter ending on April 30, 2025, have not been provided yet. The previous results were reported on February 27, 2025, through the Transfer Agent. Before that, on January 31, 2025, the results were released after hours. The results for the quarter ending on October 31, 2024, were not provided on time. However, on August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuations metrics, stock price summary, and dividends and splits information for a specific company.Financials:
- Cash flow: Operating cash flow TTM is $110,563,000,320 and levered free cash flow TTM is $84,726,874,112.
- Balance sheet: Total cash MRQ is $67,150,000,128, total debt MRQ is $104,590,000,128, current ratio MRQ is 1.037, book value per share MRQ is $4.837, total cash per share MRQ is $4.379, and total debt to equity MRQ is 140.968.
- Profit margin: 26.306%
- Fiscal year ends: September 30, 2023
- Income statement: EBITDA is $131,393,000,000, revenue TTM is $381,623,009,280, diluted EPS TTM is $6.43, gross profit TTM is $169,148,000,000, revenue per share TTM is $24.537, net income to common TTM is $100,389,003,264, quarterly revenue growth is -4.3%, and quarterly earnings growth YoY is -2.2%.
- Operating margin: 30.743%
- Most recent quarter: March 31, 2024
- Return on assets TTM: 22.073999%
- Return on equity TTM: 147.25%
Stock statistics:
- Short ratio: 1.53
- Float shares: 15,308,320,742
- Shares short: 99,287,450
- Average 10-day volume: 46,860,048
- Average 90-day volume: 57,498,254
- Shares outstanding: 15,334,099,968
- Percent held by insiders: 5.22%
- Percent held by institutions: 57.589%
- Short percent of shares outstanding: 0.65%
Valuations metrics:
- PEG ratio: 26.319502
- Forward PE: 26.319502
- Trailing PE: 29.59409
- Enterprise value: $2,950,762,332,160
- Price to book MRQ: 39.3405
- Price to sales TTM: 7.646095
- Enterprise to EBITDA: 22.763
- Enterprise to revenue: 7.732
- Market capitalization: $2,917,925,650,432
Stock price summary:
- Beta: 1.264
- 50-day moving average: $176.2646
- 200-day moving average: $181.0429
- Fifty-two week low: $164.08
- Fifty-two week high: $199.62
- Fifty-two week change: 6.853%
Dividends and splits:
- Payout ratio: 14.93%
- Dividend date: May 16, 2024
- Last split date: August 31, 2020
- Ex-dividend date: May 10, 2024
- Last split factor: 4-for-1 split
- Forward annual dividend rate: $1
- 5-year average dividend yield: 0.73%
- Forward annual dividend yield: 0.5255%
- Trailing annual dividend rate: $0.97
- Trailing annual dividend yield: 0.5097%
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. Financing activities show significant fluctuations, with large amounts being spent on common stock repurchase and debt issuance/payment.
4. Investing activities also vary, with notable amounts spent on the sale and purchase of investments.
5. The end cash position has been relatively stable, showing the company's ability to manage its cash flow effectively.
6. Interest paid and income tax paid have also fluctuated, impacting the company's overall cash flow position.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average estimated EPS is $1.33, which is higher than the EPS of $1.26 from the same quarter a year ago. The range of estimates is between $1.27 and $1.36, as provided by 26 analysts.
2. For the next quarter ending on September 30, 2024, the average estimated EPS is $1.53, compared to $1.46 from the previous year. The estimates range from $1.44 to $1.63, based on 25 analysts' forecasts.
3. Looking at the current fiscal year ending on September 30, 2024, the average estimated EPS is $6.59, an increase from the previous year's EPS of $6.13. The analysts' estimates range from $6.43 to $6.92, with insights from 39 analysts.
4. For the next fiscal year ending on September 30, 2025, the average estimated EPS is $7.23, with a range of estimates between $6.40 and $7.90. This forecast is based on the input of 39 analysts.
Overall, the analysts are predicting growth in earnings per share both for the upcoming quarters and the next fiscal years, indicating positive expectations for the company's performance.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $83,776,900,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 24.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $92,375,300,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 24.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $386,681,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 37.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $411,555,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 37.
These estimates indicate a generally positive outlook for the company's sales performance, with expected growth in both the short term and the long term.
Growth estimates
Based on the consensus estimates provided, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.6%.
2. Next Quarter: The estimated growth rate for the next quarter is 4.8%.
3. Current Year: The estimated growth rate for the current year is 7.5%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 11%.
These estimates suggest a positive growth trend for the company, with a slightly lower growth rate expected in the near term compared to the historical average. However, the company is still projected to experience solid growth both in the short and long term according to analyst consensus.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD
Based on these forecasts, it seems that the analysts are generally optimistic about the future price of the security, with a median and average price above the current price. However, there is a wide range between the low and high forecasts, indicating some uncertainty or differing opinions among analysts.
MACD of 0IFK
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
